

Assessment of SARS-CoV-2 infection by Reverse transcription-PCR and serology in the Paris area: a cross-sectional study

Robert Cohen,^{1,2,3,4} Camille Jung,^{2,5} Naim Ouldali,³ Aurelie Sellam,⁶ Christophe Batard,³ Fabienne Cahn-Sellem,⁴ Annie Elbez,³ Alain Wollner,³ Olivier Romain,³ François Corrad,³ Said Aberrane,⁷ Nathalie Soismier,⁷ Rita Creidy,⁷ Mounira Smati-Lafarge,⁷ Odile Launay,⁸ Stéphane Béchet,³ Emmanuelle Varon,⁷ Corinne Levy ^{2,3,4,5}

To cite: Cohen R, Jung C, Ouldali N, *et al.* Assessment of SARS-CoV-2 infection by Reverse transcription-PCR and serology in the Paris area: a cross-sectional study. *BMJ Paediatrics Open* 2020;**4**:e000887. doi:10.1136/bmjpo-2020-000887

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjpo-2020-000887>).

Received 23 September 2020
Revised 16 November 2020
Accepted 19 November 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Corinne Levy; corinne.levy@activ-france.fr

ABSTRACT

Background Several studies indicated that children seem to be less frequently infected with SARS-CoV-2 and are potentially less contagious than adults. To examine the spread of SARS-CoV-2, we combined both Reverse transcription-PCR testing and serology in children in the most affected region in France, Paris, during the COVID-19 epidemic.

Methods From 14 April 2020 to 12 May 2020, we conducted a cross-sectional, prospective, multicentre study. Healthy controls and pauci-symptomatic children from birth to age 15 years were enrolled by 27 ambulatory paediatricians. A nasopharyngeal swab was taken for detection of SARS-CoV-2 by Reverse transcription-PCR and a microsample of blood for micromethod serology.

Results Among the 605 children, 322 (53.2%) were asymptomatic and 283 (46.8%) were symptomatic. Reverse transcription-PCR and serology results were positive for 11 (1.8%) and 65 (10.7%) children, respectively, with no significant difference between asymptomatic and pauci-symptomatic children. Only three children were Reverse transcription-PCR-positive without any antibody response detected. The frequency of Reverse transcription-PCR SARS-CoV-2 positivity was significantly higher for children with positive than negative serology results (12.3% vs 0.6%, $p < 0.001$). Contact with a person with confirmed COVID-19 increased the odds of Reverse transcription-PCR positivity (OR 7.8, 95% CI 1.5 to 40.7) and serology positivity (OR 15.1, 95% CI 6.6 to 34.6).

Conclusion In an area heavily affected by COVID-19, after the peak of the first epidemic wave and during the lockdown, the rate of children with Reverse transcription-PCR SARS-CoV-2 positivity was very low (1.8%), but that of serology positivity was higher (10.7%). Most children with positive Reverse transcription-PCR results also had positive serology results.

Trial registration number NCT04318431.

INTRODUCTION

Since the beginning of the COVID-19 pandemic, reports from several countries indicated that the disease was less frequently

What is known about the subject?

- At this time, several studies suggested that children are less frequently infected with SARS-CoV-2 and are potentially less contagious than adults.
- Most of the studies were based on Reverse transcription-PCR SARS-CoV-2 testing, without antibody assays.

What this study adds?

- This study combining Reverse transcription-PCR testing and serology assessed the prevalence of SARS-CoV-2 infection in children in an area heavily affected by the COVID-19 pandemic.
- Among a large cohort of children (>600), 11 (1.8%) had positive Reverse transcription-PCR SARS-CoV-2 results and 65 (10.7%) had antibodies to SARS-CoV-2.
- The only factor associated with Reverse transcription-PCR SARS-CoV-2 or serology positivity was the presence of a household contact with COVID-19.

reported and less severe in children than in adults.¹⁻³ Worldwide, the number of confirmed paediatric cases seems relatively low, and they account for less than 1% of hospitalised cases and deaths.^{1 4} Although most COVID-19 cases in children are not severe, serious COVID-19 illness resulting in hospitalisation can occur in this age group, and recently, hyperinflammatory shock, with features similar to atypical Kawasaki disease, was reported in several countries.⁵⁻¹⁰

However, concerns have been raised that children could play an important role in the spread of the disease because community testing has demonstrated a significant



number of children with or without subclinical symptoms.¹¹ Indeed, if as for influenza, children could be the primary drivers of household SARS-CoV-2 transmission, then a silent spread from children who did not alert anyone to their infection could be a serious driver in the dynamics of the epidemic.¹² On the basis of this prevailing hypothesis, school closures were implemented almost ubiquitously around the world to try to halt the potential spread of COVID-19.^{13 14}

However, several studies had already shown that when SARS-CoV-2 infection was suspected (compatible clinical signs, contact with a person with COVID-19), the rate of positive Reverse transcription-PCR SARS-CoV-2 results was lower in children than in adults.^{14 15} In contrast, in Reverse transcription-PCR SARS-CoV-2-positive children, the viral load was comparable between children and adults.¹⁶ Furthermore, one study suggested that children shed infectious SARS-CoV-2.¹⁷ However, results from a systematic review of household clusters of COVID-19 revealed that only 3/31 clusters were due to a child index case, and a population-based school contact-tracing study found minimal transmission by child or teacher index cases.^{18 19} Finally, other studies suggested that children were potentially less contagious than adults, but the design of these studies does not exclude the possibility of children being more contagious than adults.^{16 20-22}

Some countries such as South Korea and Iceland have implemented widespread community testing. Both countries found children significantly under-represented in cases. In Iceland, this was true in targeted testing of high-risk groups as compared with adults (6.7% <10 years vs 13.7% ≥10 years positive cases), and in (invited) population screening, no child <10 years old was positive for SARS-CoV-2 as compared with 0.8% in the general population.²³

Of note, all these studies were based on Reverse transcription-PCR testing, but serology diagnosis is also an important tool to understand the prevalence and burden of COVID-19.²⁴ A serology survey tested adolescents in a high school in the north of France, the site of a cluster at the end of February. Of the 242 students tested, 2.7% of children ≤14 years old and 40% aged 15–17 years had positive SARS-CoV-2 serology results (IgG), which suggests a difference in susceptibility to SARS-CoV-2 among younger children.²⁵

To best approach the prevalence of SARS-CoV-2 in children at a population level, we combined both Reverse transcription-PCR testing for SARS-CoV-2 and serology in asymptomatic or pauci-symptomatic children (with mild clinical symptoms) in the Paris area, the most affected region in France, during the COVID-19 epidemic.

PATIENTS AND METHODS

Study population

This was a cross-sectional prospective, multicentre study conducted by the Association Clinique et Thérapeutique Infantile du Val de Marne network,

a research unit expert in epidemiological surveillance and clinical studies in ambulatory paediatric infectious diseases, and the University Intercommunal Créteil Hospital.²⁶ Primary care paediatricians (n=27) took part in the study from 14 April 2020 to 12 May 2020. The strategy of closing schools and the lockdown decided by the French government for the whole country started on 17 March and finished on 11 May 2020.

This study aimed to enrol children from birth to 15 years old who were consulting an ambulatory paediatrician and distributed in two groups: asymptomatic and pauci-symptomatic. Asymptomatic children were defined as children without any symptoms or signs suggesting infectious disease during the previous 7 days. They usually came for vaccination visits. In this group, we defined two subgroups of children: those previously symptomatic (fever, respiratory or digestive symptoms) between 7 days and 2 months before enrolment, and those without any previous symptoms. Pauci-symptomatic children were defined as those with fever isolated or associated with respiratory signs, such as cough, dysphagia, rhinorrhoea, diarrhoea, vomiting, cutaneous signs, taste loss and/or anosmia during the previous 7 days. Children were excluded if the clinical condition at enrolment required transfer to a paediatric emergency unit or hospitalisation.

After informing the parents of the participating children and obtaining their signed consent, an electronic case report form (eCRF) was completed by the paediatrician to collect sociodemographic data, history, contact with a person with confirmed COVID-19 by Reverse transcription-PCR for SARS-CoV-2, clinical symptoms and signs and additional positive biological tests. We also collected suspected COVID-19 contacts because of the limited availability of testing. Indeed, during the lockdown, the diagnostic Reverse transcription-PCR SARS-CoV-2 test was mainly available for patients with severe disease and/or healthcare workers, and all symptomatic individuals could not be tested. For all enrolled children, during the same visit, a nasopharyngeal (NP) swab was taken for Reverse transcription-PCR detection of SARS-CoV-2 and a microsample of blood for micromethod serology.

Power calculation

To have an appropriate proportion of confirmed Reverse transcription-PCR SARS-CoV-2-positive patients among asymptomatic and pauci-symptomatic children, with a 95% CI of ±3%, assuming a positivity proportion of <10%, which was the rate of positive Reverse transcription-PCR before the beginning of the study, we needed to enrol 300 children per group (asymptomatic and pauci-symptomatic), for 600 patients in total.

Serology

As previously reported,²⁷ paediatricians collected fingerstick whole-blood specimens and used the Biosynex COVID-19 BSS test, which was among those approved by the French National Health Authority.²⁷ A positive serology result meant that the patient had a previous SARS-CoV-2 infection: positive for IgG or IgM or both. A serology result was considered negative if results for both IgM and IgG were negative.

SARS-CoV-2 RT-PCR

As previously reported,²⁷ paediatricians collected NP specimens transported to the centralised microbiology laboratory (CHIC) for the Reverse transcription-PCR for SARS-CoV-2 analysis. NP samples were considered positive with a cycle threshold (Ct) value of <40 obtained for any gene. Amplification of two or three targets indicated that SARS-CoV-2 RNA was detected, and amplification of only one target with Ct value of <38 indicated a presumptive positive result. We defined as weakly positive any result with Ct values of >38 and <40. A sample was considered negative if the internal control was amplified but not the viral target genes. A sample was considered invalid when no amplification was obtained for the internal control.

Statistical analysis

Data were entered by using the eCRF (PHP/MySQL) and analysed by using STATA/SE V.5. For the initial analysis (univariate), quantitative data were compared by Student t-test and categorical data by χ^2 or Fisher exact test. Variables (age, clinical signs, contact, siblings and daycare attendance modalities) with p values of <0.20 on univariate analysis were included in the multivariable model. For this model, we used a logistic regression to estimate ORs and 95% CIs for factors associated with Reverse transcription-PCR SARS-CoV-2 and serology positivity. Only variables with p values of <0.05 were kept in the final model. All tests were two-sided and were considered significant at a p value of <0.05.

The study was registered at ClinicalTrials.gov.

Patient and public involvement

There were no patients or public involved in the research design, process and research findings dissemination.

RESULTS

From 14 April 2020 to 12 May 2020, 27 ambulatory paediatricians in the Paris area enrolled 605 children: 322 (53.2%) children were asymptomatic and 283 (46.8%) were pauci-symptomatic. **Table 1** presents the characteristics of the enrolled children by group. In the pauci-symptomatic group, the main signs and symptoms were fever (187, 66.3%), cough (143, 50.7%), pharyngitis (143, 50.7%), rhinitis (137, 48.4%), diarrhoea (81, 28.7%),

rash (64, 23.0%), vomiting (52, 18.8%), dysgeusia (8, 3.0%) and anosmia (5, 3.3%).

Figure 1 presents the dates of the lockdown and the number of children enrolled, by week, during the first epidemic wave in Paris.²⁸

Reverse transcription-PCR SARS-CoV-2 results were positive for 11 (1.8%) children, with no significant difference between children with and without symptoms (χ^2 , p=0.3, **table 2**). The online supplemental table 1 shows the details of the 11 positive Reverse transcription-PCR SARS-CoV-2 cases. Only three children had Reverse transcription-PCR SARS-CoV-2 positivity with a Ct value of <31.

On multivariable analysis (online supplemental table 2), contact with a person with proven COVID-19 was the only significant risk factor for Reverse transcription-PCR SARS-CoV-2 positivity (OR 7.8, 95% CI 1.5 to 40.7).

Table 2 shows the serology results by group. The age distribution of children was similar whatever the serology results, negative or positive: <3 months, 1.3% vs 1.5%; 3–30 months, 37.2% vs 26.2%; 31 months–5 years, 29.6% vs 36.9%; 6–10 years, 21.7% vs 26.2%; ≥11 years, 10.2% vs 9.2%. Serology was positive for 65 of 605 (10.7%) children, and among these, 87.3% had a confirmed or suspected contact. Children previously symptomatic during the preceding weeks were more frequently positive on serology.

Reverse transcription-PCR SARS-CoV-2 was more frequently positive for children with positive than negative serology results (12.3% vs 0.6%, p<0.001). Only three children had Reverse transcription-PCR SARS-CoV-2 positivity without any antibody response detected.

Table 3 shows serology and Reverse transcription-PCR SARS-CoV-2 results for the 543 enrolled children according to contact with a person (adult or child) with suspected or confirmed COVID-19. Only 2 of 275 (0.7%) children without any contact with a person with COVID-19 had positive Reverse transcription-PCR SARS-CoV-2 results. On multivariable analysis (online supplemental table 3), serology positivity was associated with contact with a person with proven or suspected COVID-19 (OR 15.1, 95% CI 6.6 to 34.6, and 5.8, 95% CI 2.6 to 13.2).

DISCUSSION

This study combines Reverse transcription-PCR SARS-CoV-2 and serology results to assess the prevalence of SARS-CoV-2 infection in a large cohort of children in the community. In a region strongly affected by the epidemic (Paris area), during the lockdown, as expected, very few children (1.8%) had Reverse transcription-PCR SARS-CoV-2 positivity, but the proportion with serology positivity (10.7%) was relatively high. Despite the relatively large number of children included (>600), we did not find a significant difference in rate of positive Reverse transcription-PCR or serology results between asymptomatic and pauci-symptomatic children, which

**Table 1** Characteristics of children enrolled in the study and by pauci-symptomatic and asymptomatic groups

	Overall, N=605	Pauci-symptomatic children,* n=283	Asymptomatic children		Total, n=322	P value†
			Previously symptomatic (>7 days),‡ n=118	No previous symptoms,§ n=204		
Age (years)						0.08
Mean±SD	4.9±3.9	4.8±3.7	5.6±4.3	4.7±4.1	5.0±4.2	0.1
Median	3.8	4.0	4.4	3.4	3.7	
<3 months	8 (1.3)	6 (2.1)	0	2 (1.0)	2 (0.6)	
3–30 months	218 (36.0)	98 (34.6)	37 (31.4)	83 (40.7)	120 (37.3)	
31 months–5 years	184 (30.4)	96 (33.9)	34 (28.8)	54 (26.5)	88 (27.3)	
6–10 years	134 (22.2)	61 (21.6)	29 (24.6)	44 (21.6)	73 (22.7)	
≥11 years	61 (10.1)	22 (7.8)	18 (15.2)	21 (10.3)	39 (12.1)	
Sex, male	322 (53.2)	152 (53.7)	65 (55.1)	105 (51.5)	170 (52.8)	0.8
Daycare attendance before lockdown						0.031
Home	78 (13.8)	34 (13.0)	6 (5.4)	38 (19.7)	44 (14.5)	
Childminder	55 (9.7)	24 (9.2)	10 (9.0)	21 (10.9)	31 (10.2)	
Daycare centre	135 (23.9)	66 (25.2)	29 (26.1)	40 (20.7)	69 (22.7)	
School	298 (52.7)	138 (52.7)	66 (59.5)	94 (48.7)	160 (52.6)	
Comorbidities	93 (15.4)	45 (15.9)	28 (23.7)	20 (9.8)	48 (14.9)	0.004
Prematurity	35 (6.3)	15 (5.7)	7 (6.1)	13 (7.4)	20 (6.9)	0.8
Siblings						0.3
0	115 (20.6)	57 (21.9)	18 (15.9)	40 (21.5)	58 (19.4)	
1	282 (50.5)	136 (52.3)	61 (54.0)	85 (45.7)	146 (48.8)	
≥2	162 (29.0)	67 (25.8)	34 (30.1)	61 (32.8)	95 (31.8)	

Data are n (%) unless indicated.

*Pauci-symptomatic children were those with fever isolated or associated with respiratory signs, such as cough, dysphagia, rhinorrhoea, diarrhoea, vomiting, rash, dysgeusia and/or anosmia, during the previous 7 days.

†P value compares symptomatic children, asymptomatic children previously symptomatic for >7 days and asymptomatic children without previous symptoms.

‡Previously symptomatic (fever or respiratory or digestive) between 7 days and 2 months before enrolment.

§No previous symptoms.

suggests that most children were asymptomatic after a SARS-CoV-2 infection.

Among asymptomatic children, those with no history of symptoms during the preceding weeks accounted for two-thirds of children with positive serology results (28/41), which supports the fact that asymptomatic infections are frequent in children. By contrast, history of symptoms during the preceding weeks significantly increased the risk of positive serology. However, on multivariable analysis, the only factor influencing the positivity of Reverse transcription-PCR or serology was the household contact who previously presented symptoms suggesting COVID-19. Of note, the number of siblings in the family did not significantly increase the probability of a positive Reverse transcription-PCR or serology result. Several studies have shown that children were usually infected by an adult in the family.^{18 22 29 30} In our study, the importance of familial contagion in the modalities of SARS-CoV-2 transmission is suggested by a very low Reverse transcription-PCR (0.7%)

and serology (3.6%) positivity rate for children without an infected relative and in a period of lockdown.

Among the children with Reverse transcription-PCR positivity (n=11), only three had no antibody response, and eight were positive for IgG with or without IgM positivity. This finding supports that for these three patients, infection had probably occurred some time before enrolment.

We highlight that the frequency of Reverse transcription-PCR SARS-CoV-2 positivity was significantly higher in children with positive than negative serology results (12.3% vs 0.6%, $p<0.001$). This finding highlights the difficulties in interpreting the significance of a positive Reverse transcription-PCR SARS-CoV-2 result without concomitant antibody testing after the epidemic wave. Preliminary reports suggest that children with Reverse transcription-PCR SARS-CoV-2 positivity and IgG positivity probably had little or no infectivity.^{31 32} In a study of nine patients, attempts to isolate the virus in culture




Figure 1 Number of children enrolled and total hospitalisation during the first COVID-19 epidemic wave in the Paris area.

were not successful beyond day 8 of illness onset, which could be related to the decreased infectivity beyond the first week.³³ In the study of Bullard *et al*, SARS-CoV-2

Vero cell infectivity was observed with only Reverse transcription-PCR Ct value of <24 and symptom onset to test duration of <8 days.³⁴ Infectivity was likely low for 8 of

Table 2 Results of Reverse transcription-PCR SARS-CoV-2 testing and serology in children by pauci-symptomatic and asymptomatic groups

	Overall, N=605	Pauci-symptomatic children,* n=283	Asymptomatic children		Total, n=322
			Previously symptomatic (>7 days),† n=118	No previous symptoms,§ n=204	
Reverse transcription-PCR					
Overall	11 (1.8) (0.9 to 3.2)	7 (2.5) (1.0 to 5.0)	1 (0.8) (0.0 to 4.6)	3 (1.5) (0.3 to 4.2)	4 (1.2) (0.3 to 3.1)
Definitely positive‡	5	3	0	2	2
Weakly positive¶	1	1	0	0	0
Presumptive**	5	3	1	1	2
Serology					
IgM+ and/or IgG+	65 (10.7) (8.4 to 13.5)	24 (8.5) (5.5 to 12.4)	28 (23.7)‡ (16.4 to 32.4)	13 (6.4)‡ (3.4 to 10.7)	41 (12.7) (9.3 to 16.9)
IgM+IgG-	7 (1.2) (0.5 to 2.4)	4 (1.4) (0.4 to 3.6)	2 (1.7) (0.2 to 6.0)	1 (0.5) (0.0 to 2.7)	3 (0.9) (0.2 to 2.7)
IgM+IgG+	32 (5.3) (3.6 to 7.4)	12 (4.2) (2.2 to 7.3)	17 (14.4)‡ (8.6 to 22.1)	3 (1.5)‡ (0.3 to 4.2)	20 (6.2) (3.8 to 9.4)
IgM-IgG+	26 (4.2) (2.8 to 6.2)	8 (2.8) (1.2 to 5.5)	9 (7.6) (3.5 to 14.0)	9 (4.4) (2.0 to 8.2)	18 (5.6) (3.3 to 8.7)

Data are n (%) (95% CI).

*Pauci-symptomatic children were those with fever isolated or associated with respiratory signs such as cough, dysphagia, rhinorrhoea, diarrhoea, vomiting, rash, dysgeusia and/or anosmia, during the previous 7 days.

†Previously symptomatic (fever or respiratory or digestive) between 7 days and 2 months before enrolment.

‡Definitely positive: Ct value<38 obtained for two or three genes.

§No previous symptoms.

¶Weakly positive: any result with a Ct value of >38 and <40.

**Presumptive: Ct<38 obtained for only one target.

Ct, cycle threshold.



Table 3 Serology and Reverse transcription-PCR results for the 543 enrolled children according to contact with a person (adult or child) with confirmed and/or suspected COVID-19

Contact	Enrolled children				
	Overall, N=543*	Positive serology, n=63	Negative serology, n=480	Positive Reverse transcription-PCR SARS-CoV-2, n=11	Negative Reverse transcription-PCR SARS-CoV-2, n=532
Confirmed COVID-19†	93 (17.1) (14.1 to 20.6)	29 (31.2) (22.0 to 41.6)	64 (68.8) (58.4 to 78.0)	5 (5.4) (1.8 to 12.1)	88 (94.6) (87.9 to 98.2)
Suspected COVID-19‡	175 (32.2) (28.3 to 36.3)	26 (14.9) (9.9 to 21.0)	149 (85.1) (79.0 to 90.0)	4 (2.3) (0.6 to 5.7)	171 (97.7) (94.3 to 99.4)
Confirmed/suspected COVID-19	268 (49.4) (45.1 to 53.6)	55 (20.5) (15.9 to 25.9)	213 (79.5) (74.1 to 84.1)	9 (3.4) (1.5 to 6.3)	259 (96.6) (93.7 to 98.5)
No contact	275 (50.6) (46.4 to 54.9)	8 (2.9) (1.3 to 5.7)	267 (97.1) (94.3 to 98.7)	2 (0.7) (0.1 to 2.6)	273 (99.3) (97.4 to 99.9)

Data are n (%) (95% CI).

*543 available data among 605 enrolled patients.

†Confirmed by Reverse transcription-PCR SARS-CoV-2.

‡Suspected symptoms suggestive of COVID-19 because of the limited availability of testing.

the 11 Reverse transcription-PCR SARS-CoV-2-positive children. Indeed, only three children had a Ct value of <31.

Our study has several limitations. First, the role of assumed household transmission has probably been overestimated because of the well-followed lockdown in France.³⁵ Indeed, more than 86.5% of children with Reverse transcription-PCR SARS-CoV-2 or serology positivity had a confirmed or suspected COVID-19 household contact. However, our rate of positive serology for children in the Paris area was similar to the rate observed for hospitalised children (11.7%) and school children (8.8%).^{22,36} Second, the ability to successfully collect NP swabs properly could be more difficult in young children and could significantly affect the results and be a factor contributing to the low Reverse transcription-PCR positivity prevalence observed in our population. However, the paediatricians who performed the study were all involved for many years in a pneumococcal NP carriage study (started in 2001 and currently ongoing) and were particularly well trained to collect appropriate NP samples.³⁷

School closure or limitation (reduced number of students or days of attendance) has a major impact on children's development and access to learning.³⁸ Therefore, the usefulness of school closure or limitation needs evaluation in controlling the COVID-19 epidemic.³⁹ We plan to renew this study after the full reopening of schools and daycare centres in the Paris area. To better assess the transmission of SARS-CoV-2 in children and to elucidate their role in the transmission, serial testing of all household members is needed.

Author affiliations

- ¹Paediatric Department, Centre Hospitalier Intercommunal de Créteil, Creteil, Île-de-France, France
- ²Université Paris Est, IMRB-GRC GEMINI, Créteil, France
- ³ACTIV, Creteil, France
- ⁴AFPA, Paris, France
- ⁵Centre Hospitalier Intercommunal de Creteil, Creteil, Île-de-France, France
- ⁶Seine Saint Denis, Hôpital Jean Verdier, Bondy, France
- ⁷Microbiology, Centre Hospitalier Intercommunal de Créteil, Creteil, Île-de-France, France
- ⁸Hôpital Cochin, Paris, Île-de-France, France

Acknowledgements We are grateful to the investigators of the COVILLE study Network: Akou'ou M.H, Auvrignon A, Belaroussi N, Benani M, Cambier Nappo E, Chartier Albrech C, Coicadan L, Condor R, D'Acremont G, D'Ovidio N, De Brito B, Deberdt P, Delatour A, Gorde-Grosjean S, Louvel M, Michot-Cottias A-S, Ravilly S, Seror E and Turberg-Romain C; Adjemian S, Auffroy O, Begard M, Harant J, Mouaouya M, Receveau F and Sigere ML for technical assistance; Cuquemelle A for secretarial assistance; the Association Clinique et Thérapeutique Infantile du Val de Marne team: Ramay I, Prieur C; Prieur A, Borg M, Meyet L, Levy J and Zemmour E (Association Clinique et thérapeutique Infantile du Val de Marne); and the CRC team: Brussieux M and Hoffart C from the Clinical Research Centre of the CHI Créteil.

Contributors RC, CL, NO, CJ, OL and EV designed the study. RC, CL, NO, CJ, OL, AS, CB, AE, FC, FC-S, AW, OR and EV analysed and interpreted the data and drafted the article. SB and CL performed the statistical analysis. EV, SA, NS, RC and MS-L performed the microbiological analysis. All authors revised and approved the manuscript.

Funding This work was supported by the French Ministry of Health DGOS PHRC regional IDF 2020 number AOR20095.

Competing interests RC, CL and EV received personal fees and non-financial support from Pfizer. RC reports personal fees from Merck, GSK, Sanofi and AstraZeneca outside the submitted work. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Patient consent for publication Not required.

Ethics approval The study protocol was approved by an ethics committee (CPP IDF IX no. 08–022). Parents of all infants and children provided written informed consent.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Deidentified data available upon reasonable request after signed DTA.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Corinne Levy <http://orcid.org/0000-0002-1927-6360>

REFERENCES

- Castagnoli R, Votto M, Licari A, *et al*. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents. *JAMA Pediatr* 2020;174:882.
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. *JAMA* 2020;323:1239–42.
- Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* 2020;109:1088–95.
- CDC COVID-19 Response Team. Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:422–6.
- Riphagen S, Gomez X, Gonzalez-Martinez C, *et al*. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet* 2020;395:1607–8.
- Belot A, Antona D, Renolleau S, *et al*. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. *Euro Surveill* 2020;25.
- Davies P, Evans C, Kanthimathinathan HK, *et al*. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. *Lancet Child Adolesc Health* 2020;4:669–77.
- Feldstein LR, Rose EB, Horwitz SM, *et al*. Multisystem inflammatory syndrome in U.S. children and adolescents. *N Engl J Med* 2020;383:334–46. doi:10.1056/NEJMoa2021680
- Toubiana J, Poirault C, Corsia A, *et al*. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ* 2020;369:m2094.
- Verdoni L, Mazza A, Gervasoni A, *et al*. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet* 2020;395:1771–8.
- Dong Y, Mo X, Hu Y, *et al*. Epidemiology of COVID-19 among children in China. *Pediatrics* 2020;145:e20200702.
- Tsang TK, Fang VJ, Chan K-H, *et al*. Individual correlates of infectivity of influenza A virus infections in households. *PLoS One* 2016;11:e0154418.
- Eubank S, Eckstrand I, Lewis B, *et al*. Commentary on Ferguson, *et al.*, "impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand". *Bull Math Biol* 2020;82:52. doi:10.1007/s11538-020-00726-x
- Munro APS, Faust SN. Children are not COVID-19 super spreaders: time to go back to school. *Arch Dis Child* 2020;105:618–9. doi:10.1136/archdischild-2020-319474
- Levy C. Changes in RT-PCR-positive SARS-CoV-2 rates in adults and children according to the epidemic stages. *Pediatr Infect Dis J* 2020. doi:10.1101/2020.05.18.20098863
- Jones TC, Mühlemann B, Veith T. An analysis of SARS-CoV-2 viral load by patient age, 2020. Available: https://zoosencharitedei/fileadmin/user_upload/microsites/m_cc05/virologie-ccm/dateien_upload/Weitere_Dateien/analysis-of-SARS-CoV-2-viral-load-by-patient-age.pdf
- L'Huillier AG, Torriani G, Pigny F, *et al*. Culture-Competent SARS-CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents. *Emerg Infect Dis* 2020;26:2494–7.
- Zhu Y, Bloxham CJ, Hulme KD, *et al*. Children are unlikely to have been the primary source of household SARS-CoV-2 infections. *medRxiv* 2020.
- Zhang J, Litvinova M, Liang Y, *et al*. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science* 2020;368:1481–6.
- RIVM. The National Institute for public health and the environment (RIVM). children and COVID-19, 2020. Available: <https://www.rivm.nl/en/novel-coronavirus-covid-19/children-and-covid-19> [Accessed 7 May 2020].
- Danis K, Epaulard O, Bénet T, *et al*. Cluster of coronavirus disease 2019 (COVID-19) in the French Alps, February 2020. *Clin Infect Dis* 2020;71:825–32.
- Fontanet A, Grant R, Tondeur L. SARS-CoV-2 infection in primary schools in northern France: a retrospective cohort study in an area of high transmission, 2020. Available: <https://www.medrxiv.org/content/101101/2020062520140178v2>
- Gudbjartsson DF, Helgason A, Jonsson H. Spread of SARS-CoV-2 in the Icelandic population. *N Engl J Med* 2020. doi:10.1056/NEJMoa2006100
- Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. *JAMA* 2020;323:2249.
- Fontanet A, Tondeur L, Madec Y, *et al*. Cluster of COVID-19 in northern France: a retrospective closed cohort study. *SSRN Journal* 2020.
- Levy C, Vie le Sage F, Varon E, *et al*. Pediatric ambulatory and hospital networks for surveillance and clinical epidemiology of community-acquired infections. *J Pediatr* 2018;194:269–70.
- Gaborieau L, Delestrain C, Bensaïd P, *et al*. Epidemiology and clinical presentation of children hospitalized with SARS-CoV-2 infection in suburbs of Paris. *J Clin Med* 2020;9. doi:10.3390/jcm9072227. [Epub ahead of print: 14 Jul 2020].
- Caducée.net. Covid-19: Paris area epidemiologic situation, 2020. Available: <https://www.caducee.net/actualite-medicale/14774/covid-19-la-situation-epidemiologique-en-ile-de-france.html>
- Li W, Zhang B, Lu J. The characteristics of household transmission of COVID-19. *Clin Infect Dis* 2020;ciaa450. doi:10.1093/cid/ciaa450
- Somekh E, Gleyzer A, Heller E, *et al*. The role of children in the dynamics of intra family coronavirus 2019 spread in densely populated area. *Pediatr Infect Dis J* 2020;39:e202–4.
- Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 test sensitivity - a strategy for containment. *N Engl J Med* 2020;383:e120.
- Posfay-Barbe KM, Wagner N, Gauthey M, *et al*. COVID-19 in children and the dynamics of infection in families. *Pediatrics* 2020;146. doi:10.1542/peds.2020-1576. [Epub ahead of print: 26 May 2020].
- Wölfel R, Corman VM, Guggemos W, *et al*. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020;581:465–9.
- Bullard J, Dust K, Funk D, *et al*. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin Infect Dis* 2020. doi:10.1093/cid/ciaa638. [Epub ahead of print: 22 May 2020].
- Wu J, Huang Y, Tu C, *et al*. Household transmission of SARS-CoV-2, Zhuhai, China, 2020. *Clin Infect Dis* 2020;71:2099–108.
- Sermet-Gaudelus I, Temmam S, Huon C. Prior infection by seasonal coronaviruses does not prevent SARS-CoV-2 infection and associated multisystem inflammatory syndrome in children, 2020. Available: <https://www.medrxiv.org/content/101101/2020062920142596v1>
- Ouldali N, Cohen R, Levy C, *et al*. Pneumococcal susceptibility to antibiotics in carriage: a 17 year time series analysis of the adaptive evolution of non-vaccine emerging serotypes to a new selective pressure environment. *J Antimicrob Chemother* 2019;74:3077–86.
- UNESCO. Adverse consequences of school closures, 2020. Available: <https://en.unesco.org/covid19/educationresponse/consequences>
- Davies NG, Klepac P, Liu Y, *et al*. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med* 2020;26:1205–11.